Amgen CEO touts blockbuster potential of D-mab

Amgen CEO Kevin Sharer dropped by The Wall Street Journal to tout the company's chances in developing denosumab (D-mab) into a badly needed blockbuster. The discovery program began in an Amgen lab when researchers observed that one of the knockout mice it had developed during gene disabling research work had grown huge. "We noticed, hey that's a really big mouse," Sharer told the Journal. "It's really got big bones." 

It's also got really big market potential. Amgen believes that D-mab, which blocks the protein expressed by the gene knocked out in the mice, is worth at least a billion dollars a year, which would make up for some of the market it has lost in anemia drugs. Sharer also said that the drug would be priced closer to $1,000 a year--a fraction of the $10,000 a year tab that many biologics run.

- read the report in the Wall Street Journal

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."